Answers are grounded in this paper and cite their sources.
Intralesional therapy for recurrent melanoma is well-established for palpable lesions, however the benefit of ultrasound-guided (US) injections for non-palpable melanoma has not been well-established. This study evaluates the safety and efficacy of US-guided injection of talimogene laherparepvec (T-VEC) in the treatment of recurrent melanoma. A single-institution retrospective chart review was conducted of patients who received T-VEC between 2018 and 2023. T-tests, Fisher’s exact tests and Chi-squared tests compared patient and treatment characteristics, side effects and outcomes between US-guided and non-US guided injections. Of 36 patients, 11 (31 %) underwent US-guided and 25 (69 %) underwent non-US-guided T-VEC injections. The most common side effects in both groups were fever and chills. The US-guided cohort had no local or systemic complications while the non-US guided group had three patients with complications. Similar response (complete or partial) rates (63.6 % US guided vs 60 % non-US guided) and progression (36.4 % US-guided vs 36 % non-US guided) occurred among the cohorts (p = 0.8). Six-month survival after starting T-VEC treatment was 72.7 % in US-guided and 76 % in non-US guided (p = 0.84). US-guided injections for non-palpable recurrent melanoma are safe and demonstrate similar efficacy to non-US-guided injections, which increases treatment options for some patients.
No takes yet. Share an insight, caveat, or question.
Waldron et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: